Novartis (Cardioxane License) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

Novartis (Cardioxane License) General Information

Description

A license for cardio-protective agent used to prevent chronic cumulative cardio-toxicity. The drug is used to prevent the cardiotoxicity of anthracycline chemotherapy for patients with advanced and metastatic breast cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • P.O. Box
  • 4002 Basel
  • Switzerland
Primary Industry
Buildings and Property
Other Industries
Other Commercial Services
Pharmaceuticals
Acquirer
Clinigen
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • P.O. Box
  • 4002 Basel
  • Switzerland

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Novartis (Cardioxane License) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Novartis (Cardioxane License)‘s full profile, request access.

Request a free trial

Novartis (Cardioxane License) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Novartis (Cardioxane License)‘s full profile, request access.

Request a free trial

Novartis (Cardioxane License) FAQs

  • Where is Novartis (Cardioxane License) headquartered?

    Novartis (Cardioxane License) is headquartered in Basel, Switzerland.

  • What industry is Novartis (Cardioxane License) in?

    Novartis (Cardioxane License)’s primary industry is Buildings and Property.

  • Is Novartis (Cardioxane License) a private or public company?

    Novartis (Cardioxane License) is a Private company.

  • What is the current valuation of Novartis (Cardioxane License)?

    The current valuation of Novartis (Cardioxane License) is .

  • What is Novartis (Cardioxane License)’s current revenue?

    The current revenue for Novartis (Cardioxane License) is .

  • Who are Novartis (Cardioxane License)’s investors?

    Novartis has invested in Novartis (Cardioxane License).

  • When was Novartis (Cardioxane License) acquired?

    Novartis (Cardioxane License) was acquired on 26-Mar-2013.

  • Who acquired Novartis (Cardioxane License)?

    Novartis (Cardioxane License) was acquired by Clinigen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »